Two years after Germany’s Fresenius Medical Care walked away from a 2017 $4.3 billion deal to acquire Akorn Pharmaceuticals, the Illinois-based company filed for protection under U.S. bankruptcy laws in an attempt to restructure for a potential sale.

Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.

Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.

Two months after filing for 11 bankruptcy, Bind Therapeutics accepted a “stalking horse” bid from Pfizer.